ASX SMALL CAPS

articles with this tag

ANP to Rapidly Advance to Phase IIb Trial After Dosing Results Exceed Expectations

ANP to Rapidly Advance to Phase IIb Trial After Dosing Results Exceed Expectations

One ASX biotech that is making progress in DMD therapy and hoping to shake up an industry set to be worth US$4 billion by 2023 is Antisense Therapeutics (ASX:ANP).

ASX Junior Has Early Success With K9 Cancer Trials: Human Trials Await

ASX Junior Has Early Success With K9 Cancer Trials: Human Trials Await

One ASX listed clinical stage oncology company is developing novel targeted cancer therapeutics for both humans and animals.

Game Changer? ASX Stock Reverse Engineering Cannabis Plants

Game Changer? ASX Stock Reverse Engineering Cannabis Plants

Who is the ASX company with transforming qualities that could completely disrupt the cannabis and CBD markets?

Thanks for subscribing!

X